Differential expression of PEA3 in odontogenic cysts and tumors.
PEA3
ameloblastoma
odontogenic cysts
odontogenic tumors
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
15
06
2023
received:
21
03
2023
accepted:
21
07
2023
medline:
4
9
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
PEA3 transcription factor has been identified as a downstream target of the MAPK and PI3K pathways, and PEA3 overexpression has been observed in a variety of tumor types. We aimed to evaluate PEA3 expression in odontogenic cysts and tumors and compare the expression among odontogenic lesions. In addition, the correlations between PEA3 expression and clinicopathological characteristics of conventional ameloblastoma and unicystic ameloblastoma were investigated. This study was performed on 165 samples of odontogenic cysts and tumors including 20 dentigerous cysts, 20 odontogenic keratocysts, 16 adenomatoid odontogenic tumors, 5 ameloblastic fibromas, 45 unicystic ameloblastomas, and 59 conventional ameloblastomas. The sections were immunohistochemically stained with mouse monoclonal anti-PEA3 antibody and PEA3 expression was evaluated as the immunoreactive score. PEA3 expression was absent in all dentigerous cysts (DCs) and odontogenic keratocysts, while all adenomatoid odontogenic tumors showed either no (75%) or low (25%) expression of PEA3. Most of the ameloblastic fibromas (60%) displayed no PEA3 expression. A high expression of PEA3 was observed in a substantial number of unicystic ameloblastomas (48.9%) and conventional ameloblastomas (49.2%) in our study. PEA3 expression in DCs, odontogenic keratocysts and adenomatoid odontogenic tumors were significantly different from that in conventional ameloblastomas and that in unicystic ameloblastomas (p < 0.05). The expression of PEA3 was significantly different in the age groups of unicystic ameloblastomas and histological subtypes of conventional ameloblastomas (p < 0.05). PEA3 overexpression is predominant in unicystic ameloblastomas and conventional ameloblastomas compared to other odontogenic lesions, indicating a pivotal role of PEA3 as a downstream effector of MAPK pathway in these two odontogenic lesions.
Sections du résumé
BACKGROUND
BACKGROUND
PEA3 transcription factor has been identified as a downstream target of the MAPK and PI3K pathways, and PEA3 overexpression has been observed in a variety of tumor types. We aimed to evaluate PEA3 expression in odontogenic cysts and tumors and compare the expression among odontogenic lesions. In addition, the correlations between PEA3 expression and clinicopathological characteristics of conventional ameloblastoma and unicystic ameloblastoma were investigated.
METHODS
METHODS
This study was performed on 165 samples of odontogenic cysts and tumors including 20 dentigerous cysts, 20 odontogenic keratocysts, 16 adenomatoid odontogenic tumors, 5 ameloblastic fibromas, 45 unicystic ameloblastomas, and 59 conventional ameloblastomas. The sections were immunohistochemically stained with mouse monoclonal anti-PEA3 antibody and PEA3 expression was evaluated as the immunoreactive score.
RESULTS
RESULTS
PEA3 expression was absent in all dentigerous cysts (DCs) and odontogenic keratocysts, while all adenomatoid odontogenic tumors showed either no (75%) or low (25%) expression of PEA3. Most of the ameloblastic fibromas (60%) displayed no PEA3 expression. A high expression of PEA3 was observed in a substantial number of unicystic ameloblastomas (48.9%) and conventional ameloblastomas (49.2%) in our study. PEA3 expression in DCs, odontogenic keratocysts and adenomatoid odontogenic tumors were significantly different from that in conventional ameloblastomas and that in unicystic ameloblastomas (p < 0.05). The expression of PEA3 was significantly different in the age groups of unicystic ameloblastomas and histological subtypes of conventional ameloblastomas (p < 0.05).
CONCLUSION
CONCLUSIONS
PEA3 overexpression is predominant in unicystic ameloblastomas and conventional ameloblastomas compared to other odontogenic lesions, indicating a pivotal role of PEA3 as a downstream effector of MAPK pathway in these two odontogenic lesions.
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
ETV4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-785Subventions
Organisme : Faculty of Dentistry, Mahidol University
ID : DTRS-EG-2022-04
Informations de copyright
© 2023 The Authors. Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.
Références
Jiang W, Xu Y, Chen X, Pan S, Zhu X. E26 transformation-specific variant 4 as a tumor promotor in human cancers through specific molecular mechanisms. Mol Ther-Oncolytics. 2021;22:518-527.
Wang B, Krall EB, Aguirre AJ, et al. ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition. Cell Rep. 2017;18(6):1543-1557.
Qi T, Qu Q, Li G, et al. Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer. Am J Cancer Res. 2020;10(10):3083-3105.
Bhuyan L, Nishat R, Behura SS, Mahapatra N, Kumar H. Insight into the molecular pathogenesis of odontogenic lesions. J Oral Biosci. 2021;63(1):35-44.
WHO Classification of Tumours Editorial Board.Head and neck tumours. WHO classification of tumours series. Vol 9. 5th ed. International Agency for Research on Cancer; 2022 https://publications.iarc.fr/
Johnson NR, Batstone MD, Savage NW. Management and recurrence of keratocystic odontogenic tumor: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(4):e271-e276.
Bilodeau EA, Prasad JL, Alawi F, Seethala RR. Molecular and genetic aspects of odontogenic lesions. Head Neck Pathol. 2014;8:400-410.
Wright JM, Tekkesin MS. Odontogenic tumors: where are we in 2017? J Istanb Univ Fac Dent. 2017;51(3 Suppl 1):S10-S30.
Yuan Z-Y, Dai T, Wang S-S, et al. Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets Ther. 2014;7:1733.
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue-a review. Diagn Pathol. 2014;9:221.
Tyagi N, Deshmukh SK, Srivastava SK, et al. ETV4 facilitates cell-cycle progression in pancreatic cells through transcriptional regulation of cyclin D1. Mol Cancer Res. 2018;16(2):187-196.
da Silva Marcelino BM, Parise GK, do Canto AM, et al. Comparison of immunohistochemistry and DNA sequencing for BRAF V600E mutation detection in mandibular ameloblastomas. Appl Immunohistochem Mol Morphol. 2021;29(5):390-393.
Togni L, Zizzi A, Mazzucchelli R, Santarelli A, Rubini C, Mascitti M. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis. Int J Oral Sci. 2022;14(1):1-8.
Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes. 2020;11(11):1342.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Expe Ther Med. 2020;19(3):1997-2007.
Bologna-Molina R, Ogawa I, Mosqueda-Taylor A, et al. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors. Oral Dis. 2019;25(2):481-487.
Brunner P, Bihl M, Jundt G, Baumhoer D, Hoeller S. BRAF p. V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology. Oral Oncol. 2015;51(10):e77-e78.
You Z, Xu L, Li X, Zhang J, Sun L. BRAF gene mutations in ameloblastic fibromas. Beijing Da Xue Xue Bao Yi Xue Ban = J Peking Univ Health Sci. 2019;51(1):4-8.
Oh KY, Kim JH, Cho SD, Yoon HJ, Lee JI, Hong SD. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type. Genes Chromosomes Cancer. 2022;61(8):481-490.
Pereira NB, Pereira KMA, Coura BP, et al. BRAFV 600E mutation in the diagnosis of unicystic ameloblastoma. J Oral Pathol Med. 2016;45(10):780-785.
Heikinheimo K, Huhtala J-M, Thiel A, et al. The mutational profile of unicystic ameloblastoma. J Dent Res. 2019;98(1):54-60.
Lapthanasupkul P, Laosuk T, Ruangvejvorachai P, Aittiwarapoj A, Kitkumthorn N. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;132:e180-e185.
Barrett AW, Sneddon KJ, Tighe JV, et al. Dentigerous cyst and ameloblastoma of the jaws: correlating the histopathological and clinicoradiological features avoids a diagnostic pitfall. Int J Surg Pathol. 2017;25(2):141-147.
Robinson RA. Diagnosing the most common odontogenic cystic and osseous lesions of the jaws for the practicing pathologist. Mod Pathol. 2017;30:S96-S103.
Kurppa KJ, Catón J, Morgan PR, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232(5):492-498.
Shirsat PM, Bansal S, Prasad P, Desai RS. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: an institutional study. J Oral Maxillofac Pathol: JOMFP. 2018;22(3):353-359.
Kokubun K, Yamamoto K, Akashi Y, Chujo T, Nakajima K, Matsuzaka K. Genetic study of BRAF V600E and SMO L412F mutations in Japanese patients with Ameloblastoma. Int J Surg Pathol. 2022;30(4):378-384.
Ebeling M, Scheurer M, Sakkas A, Pietzka S, Schramm A, Wilde F. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature. Med Oncol. 2023;40(6):163.